Table 1.
Patient and transplantation characteristics
| Characteristics | Non-cGVHD (n=31) | cGVHD (n=34) | P-value |
| Age (year) | |||
| Median | 34 | 30 | 0.26 |
| Range | 18–66 | 15–61 | |
| Sex | |||
| Male | 20 (65) | 22 (65) | 0.99 |
| Female | 11 (35) | 12 (35) | |
| Diagnosis | |||
| AML | 15 (48) | 17 (50) | 0.53 |
| ALL | 7 (23) | 13 (38) | |
| CML | 5 (16) | 1 (3) | |
| MDS | 3 (10) | 1 (3) | |
| NHL | 1 (3) | 2 (6) | |
| Disease status at HSCT | |||
| Standard risk | 26 (84) | 28 (82) | 0.88 |
| High risk | 5 (16) | 6 (18) | |
| Conditioning regimens | |||
| Myeloablative | 27 (87) | 29 (85) | 0.84 |
| Reduced intensity conditionings | 4 (13) | 5 (15) | |
| Stem cell source | |||
| Bone marrow | 4 (13) | 5 (15) | 0.84 |
| Peripheral blood stem cells | 27 (87) | 29 (85) | |
| Stem cell donors | |||
| Related | 26 (84) | 26 (76) | 0.47 |
| Unrelated | 5 (16) | 8 (24) | |
| HLA-identical | 28 (90) | 27 (79) | 0.23 |
| HLA-mismatched | 3 (10) | 7 (21) | |
| aGVHD after HSCT | |||
| None | 18 (58) | 15 (44) | 0.27 |
| Grades ≥II | 13 (42) | 19 (56) | |
| GVHD involvement | |||
| Skin | 21 (62) | ||
| Eye | 1 (3) | ||
| Oral mucosa | 4 (12) | ||
| Liver | 4 (12) | ||
| Lung | 9 (26) | ||
| GI | 8 (24) | ||
| Genital | 1 (3) | ||
| Joint | 3 (8) | ||
| NIH global severity | |||
| Mild | 1 (3) | ||
| Moderate | 19 (56) | ||
| Severe | 14 (41) |
Data are expressed as number (percentage) except age. GVHD, graft-versus-host disease; cGVHD, chronic GVHD; aGVHD, acute GVHD; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; HSCT, hematopoietic stem cell transplantation; HLA, human leukocyte antigen; GI, gastrointestinal tract; NIH, National Institutes of Health